About: The Expanding Role of the COX Inhibitor/Opioid Receptor Agonist Combination in the Management of Pain

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Expanding Role of the COX Inhibitor/Opioid Receptor Agonist Combination in the Management of Pain Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	The Expanding Role of the COX Inhibitor/Opioid Receptor Agonist Combination in the Management of Pain
Creator	Cheng, · Paladini, Antonella Pergolizzi, Joseph Rekatsina, Martina Varrassi, Giustino Zis, Panagiotis Yeam, Teng
Source	Medline; PMC
abstract	Pain management in both outpatient and inpatient settings demands a multidisciplinary approach entailing medical, physical and psychological therapies. Among these, multimodal analgesic regimens stand out as a promising treatment options. Cyclo-oxygenase (COX) inhibitor/opioid receptor agonist combinations hold great potential as effective pillars in the multimodal pain management by providing adequate analgesia with fewer safety risks due to COX inhibitors’ opioid-sparing effect. Thus, these combinations, either freely or in fixed-dose formulation, offer a feasible option for the prescribing clinicians who seek to maximise therapeutic effect while simultaneously minimise adverse effects. The selection of the appropriate non-steroidal anti-inflammatory drug (NSAID) and opioid agent at optimal doses is essential. It should be tailored to the patients’ analgesic necessities, and his/her gastrointestinal and cardiovascular risk, and potential concurrent aspirin use. Moreover, it should allow for addiction risk and the potential opioid-induced bowel dysfunction and constipation. To ensure an optimal match between the characteristics of the patient and the properties of the chosen medication, and to guide adequate and well-tolerated treatment decisions, it is of paramount importance to expand clinicians’ knowledge of the currently available COX inhibitor/opioid receptor agonist combinations. This invited narrative review deals with the literature evidence covering the components of multimodal opioid-sparing analgesic regimens. Also, it provides insights into the clinically relevant choice criteria to ensure a patient-tailored analgesia.
has issue date	2020-08-04(xsd:dateTime)
bibo:doi	10.1007/s40265-020-01369-x
bibo:pmid	32749653
has license	cc-by-nc
sha1sum (hex)	3a77834bcc54964e9171b74f33d19a5aa53e4759
schema:url	https://doi.org/10.1007/s40265-020-01369-x
resource representing a document's title	The Expanding Role of the COX Inhibitor/Opioid Receptor Agonist Combination in the Management of Pain
has PubMed Central identifier	PMC7401469
has PubMed identifier	32749653
schema:publication	Drugs
resource representing a document's body	covid:3a77834bcc54964e9171b74f33d19a5aa53e4759#body_text
is schema:about of	named entity 'great' named entity 'nonsteroidal anti-inflammatory drug' named entity 'potential' named entity 'multidisciplinary approach' named entity 'COX inhibitor' named entity 'therapeutic' named entity 'inhibitors' named entity 'EVIDENCE' named entity 'FIXED' named entity 'GASTROINTESTINAL' named entity 'BOWEL DYSFUNCTION' named entity 'SETTINGS' named entity 'COMPONENTS' named entity 'NONSTEROIDAL ANTI-INFLAMMATORY DRUG' named entity 'GREAT' named entity 'COX INHIBITOR' named entity 'RISK' named entity 'PHYSICAL' named entity 'DECISIONS' named entity 'MATCH' named entity 'STAND' named entity 'OPIOID' covid:arg/3a77834bcc54964e9171b74f33d19a5aa53e4759 named entity 'analgesic' named entity 'psychological therapies' named entity 'doses' named entity 'bowel' named entity 'inhibitor' named entity 'guide' named entity 'analgesic' named entity 'gastrointestinal' named entity 'optimal match' named entity 'clinically relevant' named entity 'COX inhibitors' named entity 'opioid' named entity 'analgesia' named entity 'Opioid Receptor Agonist' named entity 'armamentarium' named entity 'adverse events' named entity 'pain management' named entity 'COX inhibitor' named entity 'paracetamol' named entity 'tramadol' named entity 'iveco' named entity 'ketoprofen' named entity 'lysine' named entity 'outpatient and inpatient' named entity 'low back pain' named entity 'NSAID' named entity 'chronic pain' named entity 'adherence to treatment' named entity 'non-significant' named entity 'adverse effects' named entity 'scientific journal' named entity 'antiinflammatory' named entity 'tramadol' named entity 'dexketoprofen' named entity 'hypovolaemia' named entity 'ICMJE' named entity 'analgesia' named entity 'dexketoprofen' named entity 'musculoskeletal conditions' named entity 'analgesic medications' named entity 'tramadol' named entity 'opioid receptor agonist' named entity 'life-threatening' named entity 'codeine' named entity 'pain relief' named entity 'opioid' named entity 'extended-release formulation' named entity 'cardiovascular' named entity 'analgesia' named entity 'analgesic' named entity 'postoperative pain' named entity 'Global Burden of Disease Study'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software